Prana Biotechnology (PRAN) Earns News Impact Rating of 0.17
Media coverage about Prana Biotechnology (NASDAQ:PRAN) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Prana Biotechnology earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 44.5207734414946 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Prana Biotechnology (NASDAQ:PRAN) traded up $0.05 during midday trading on Friday, reaching $3.24. 10,741 shares of the company’s stock were exchanged, compared to its average volume of 43,904. Prana Biotechnology has a 1-year low of $1.52 and a 1-year high of $4.58.
Separately, ValuEngine raised shares of Prana Biotechnology from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th.
About Prana Biotechnology
Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders.
Receive News & Ratings for Prana Biotechnology Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.